sprite-preloader
Anzeige
Mehr »
Samstag, 15.12.2018 Börsentäglich über 12.000 News von 601 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrSoftBank returns to back synthetic biology firm Zymergen in a $400M series C round
FrIdera's TLR9-Yervoy combo sees 'impressive' disease control in PD-1-refractory melanoma
FrGuardant to develop CDx and TMB liquid biopsy tests for AstraZeneca's targeted cancer therapies
FrEli Lilly and Evidation expand digital biomarker collaboration to data from smartphones and wearables
FrBellicum reports first data on 'controllable' CAR-T
FrChutes & Ladders-Gilead swipes Roche pharma chief for CEO post
FrSensorion's vertigo drug hits tolerability endpoint in phase 2
FrAxovant buys more gene therapies, setting it up for a busy 2019
DoOwkin launches global patient data sharing network for training AIs
DoCRISPR controls obesity in mice by amplifying rather than editing genes
DoFDA clears AR safety warning system for minimally invasive surgeries
DoCould a once-abandoned obesity drug be revived in osteoporosis?
DoSunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint
DoAmag merges with Perosphere, adding NOAC antidote
DoNeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients
DoBiogen bails on AGTC after ocular gene therapy flunks trial
DoBiofrontera cleared of wrongdoing in Nasdaq IPO
DoFDA hails 2018 as bumper year for drug development successes
DoAstraZeneca links with Cancer Research UK to debut new functional genomics center
MiTrialSpark debuts first clinical trial sites as part of deal with Novartis
MiTarget PharmaSolutions closes out the year with a pair of partnerships
MiParexel and Eli Lilly team up in effort to bolster clinical trial R&D program in China
MiCancer-killing virus plus PD-1 and MEK inhibitors make for a 3-pronged attack on melanoma
MiRoche to develop new dMMR pan-cancer test for Merck's Keytruda immunotherapy
MiGenSight rebuilds its case for LHON gene therapy, eyeing filing next year